Triple

T20301241
Position Surface form Disambiguated ID Type / Status
Subject Brilinta E505483 entity
Predicate hasActiveIngredient P12771 FINISHED
Object ticagrelor NE NERFINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: ticagrelor | Statement: [Brilinta, hasActiveIngredient, ticagrelor]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: ticagrelor
Context triple: [Brilinta, hasActiveIngredient, ticagrelor]
  • A. Brilinta
    Brilinta is a prescription antiplatelet medication (ticagrelor) used to reduce the risk of heart attack, stroke, and cardiovascular death in patients with acute coronary syndrome or a history of myocardial infarction.
  • B. Plavix
    Plavix is a widely used prescription antiplatelet medication (clopidogrel) that helps prevent blood clots and reduce the risk of heart attack and stroke.
  • C. dabigatran
    Dabigatran is an oral direct thrombin inhibitor anticoagulant used to prevent and treat blood clots and reduce the risk of stroke in patients with conditions like atrial fibrillation.
  • D. apixaban
    Apixaban is an oral anticoagulant (factor Xa inhibitor) used to prevent and treat blood clots and reduce the risk of stroke in patients with conditions such as atrial fibrillation.
  • E. Xarelto
    Xarelto is a widely used prescription anticoagulant (blood thinner) that helps prevent and treat blood clots and reduce the risk of stroke in certain patients.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: ticagrelor
Target entity description: Ticagrelor is an oral antiplatelet medication used to reduce the risk of cardiovascular events such as heart attack and stroke in patients with acute coronary syndromes or a history of myocardial infarction.
  • A. Brilinta chosen
    Brilinta is a prescription antiplatelet medication (ticagrelor) used to reduce the risk of heart attack, stroke, and cardiovascular death in patients with acute coronary syndrome or a history of myocardial infarction.
  • B. Plavix
    Plavix is a widely used prescription antiplatelet medication (clopidogrel) that helps prevent blood clots and reduce the risk of heart attack and stroke.
  • C. dabigatran
    Dabigatran is an oral direct thrombin inhibitor anticoagulant used to prevent and treat blood clots and reduce the risk of stroke in patients with conditions like atrial fibrillation.
  • D. apixaban
    Apixaban is an oral anticoagulant (factor Xa inhibitor) used to prevent and treat blood clots and reduce the risk of stroke in patients with conditions such as atrial fibrillation.
  • E. Xarelto
    Xarelto is a widely used prescription anticoagulant (blood thinner) that helps prevent and treat blood clots and reduce the risk of stroke in certain patients.
  • F. None of above.

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e0b4b8ab648190906e18538c250148 completed April 16, 2026, 10:06 a.m.
NER Named-entity recognition batch_69e6770c700c81909da247cef0d0f1eb completed April 20, 2026, 6:57 p.m.
Created at: April 16, 2026, 11:17 a.m.